Abbott agrees to pay over $384 million to settle infant formula contamination claims
Published · Updated
What happened
Abbott Laboratories agreed to pay more than $384 million to settle allegations connected to contaminated infant formula made at facilities in Michigan and Arizona. The agreement was announced within the past 24 hours and closes a defined legal dispute tied to product safety and manufacturing practices.
Why it matters
The settlement puts a new monetary and reputational marker on safety failures in a concentrated consumer-health market. It can shape retailer behavior, regulator scrutiny, and production planning across infant formula suppliers over the next several days and weeks.
Abbott Laboratories said on September 15 it will pay more than $384 million to resolve allegations tied to contaminated infant formula produced at facilities in Michigan and Arizona. The settlement returns attention to a product category that previously required emergency federal action when formula supply tightened. The development is mainly a corporate legal event, but it also reopens questions about plant oversight, retailer confidence, and resilience in a concentrated U.S. infant-nutrition supply chain.
Watch for
Abbott Laboratories filing with the SEC by 2026-09-18 detailing settlement accounting, reserve treatment, or operational remediation commitments U.S. Food and Drug Administration statement or enforcement update by 2026-09-19 referencing Abbott's Michigan or Arizona formula facilities Major U.S. retailers including Walmart, Target, or Kroger updating infant formula availability notices or supplier statements by 2026-09-19 No Abbott announcement by 2026-09-19 of production curtailments or shipment interruptions tied to the settlement
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made